Do analysts recommend NRXP or BCTX?

NRx Pharmaceuticals currently has a consensus target price of $38.25, indicating a potential upside of 1,181.41%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NRXP or BCTX more profitable?

NRx Pharmaceuticals' return on equity of 0.00% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals N/A N/A -202.92% Briacell Therap N/A -153.53% -129.26%

Do analysts recommend PEPG or BCTX?

PepGen presently has a consensus target price of $11.50, suggesting a potential upside of 506.86%. Given PepGen's stronger consensus rating and higher probable upside, analysts plainly believe PepGen is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, PEPG or BCTX?

PepGen is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A Briacell Therap N/A N/A -$26.31M -$7.92 N/A

Is PEPG or BCTX more profitable?

PepGen's return on equity of -59.89% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Briacell Therap N/A -153.53% -129.26%

Do analysts recommend ANIX or BCTX?

Anixa Biosciences currently has a consensus target price of $8.50, suggesting a potential upside of 144.96%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Anixa Biosciences is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ANIX or BCTX more profitable?

Anixa Biosciences' return on equity of -71.12% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% Briacell Therap N/A -153.53% -129.26%

Do analysts recommend BCTX or SPRB?

Spruce Biosciences has a consensus price target of $162.63, suggesting a potential upside of 267.14%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Spruce Biosciences 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64

Is BCTX or SPRB more profitable?

Briacell Therap's return on equity of -153.53% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Spruce Biosciences N/A -155.40% -101.67%

Do analysts recommend LIXT or BCTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, LIXT or BCTX?

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lixte Biotechnology N/A N/A -$6.01M -$1.13 N/A Briacell Therap N/A N/A -$26.31M -$7.92 N/A

Is LIXT or BCTX more profitable?

Lixte Biotechnology's return on equity of -134.91% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -134.91% -95.61% Briacell Therap N/A -153.53% -129.26%

Briacell Therap (BCTX) Competitors

$3.31 -0.05 (-1.49%)

As of 01:44 PM Eastern

Compare

BCTX vs. NRXP, PEPG, ANIX, SPRB, and LIXT

Should you buy Briacell Therap stock or one of its competitors? MarketBeat compares Briacell Therap with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Briacell Therap include NRx Pharmaceuticals (NRXP), PepGen (PEPG), Anixa Biosciences (ANIX), Spruce Biosciences (SPRB), and Lixte Biotechnology (LIXT).

How does Briacell Therap compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

In the previous week, NRx Pharmaceuticals' average media sentiment score of 0.00 equaled Briacell Therap'saverage media sentiment score.

Company	Overall Sentiment
NRx Pharmaceuticals	Neutral
Briacell Therap	Neutral

NRx Pharmaceuticals' return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
Briacell Therap	N/A	-153.53%	-129.26%

NRx Pharmaceuticals currently has a consensus target price of $38.25, indicating a potential upside of 1,181.41%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Briacell Therap has lower revenue, but higher earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	87.92	-$28.62M	-$1.09	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

NRx Pharmaceuticals has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

Summary

NRx Pharmaceuticals beats Briacell Therap on 8 of the 12 factors compared between the two stocks.

How does Briacell Therap compare to PepGen?

PepGen (NASDAQ:PEPG) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

PepGen has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

PepGen presently has a consensus target price of $11.50, suggesting a potential upside of 506.86%. Given PepGen's stronger consensus rating and higher probable upside, analysts plainly believe PepGen is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, PepGen had 2 more articles in the media than Briacell Therap. MarketBeat recorded 2 mentions for PepGen and 0 mentions for Briacell Therap. PepGen's average media sentiment score of 1.04 beat Briacell Therap's score of 0.00 indicating that PepGen is being referred to more favorably in the media.

Company	Overall Sentiment
PepGen	Positive
Briacell Therap	Neutral

PepGen is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

58.0% of PepGen shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Comparatively, 0.7% of Briacell Therap shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PepGen's return on equity of -59.89% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Briacell Therap	N/A	-153.53%	-129.26%

Summary

PepGen beats Briacell Therap on 11 of the 13 factors compared between the two stocks.

How does Briacell Therap compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Anixa Biosciences has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by company insiders. Comparatively, 0.7% of Briacell Therap shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Anixa Biosciences has higher revenue and earnings than Briacell Therap. Anixa Biosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	562.14	-$10.93M	-$0.31	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

Anixa Biosciences' return on equity of -71.12% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Briacell Therap	N/A	-153.53%	-129.26%

Anixa Biosciences currently has a consensus target price of $8.50, suggesting a potential upside of 144.96%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Anixa Biosciences is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Anixa Biosciences had 7 more articles in the media than Briacell Therap. MarketBeat recorded 7 mentions for Anixa Biosciences and 0 mentions for Briacell Therap. Anixa Biosciences' average media sentiment score of 1.41 beat Briacell Therap's score of 0.00 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Anixa Biosciences	Positive
Briacell Therap	Neutral

Summary

Anixa Biosciences beats Briacell Therap on 13 of the 15 factors compared between the two stocks.

How does Briacell Therap compare to Spruce Biosciences?

Briacell Therap (NASDAQ:BCTX) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Briacell Therap's return on equity of -153.53% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Spruce Biosciences	N/A	-155.40%	-101.67%

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 0.7% of Briacell Therap shares are held by insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Spruce Biosciences had 3 more articles in the media than Briacell Therap. MarketBeat recorded 3 mentions for Spruce Biosciences and 0 mentions for Briacell Therap. Spruce Biosciences' average media sentiment score of 0.44 beat Briacell Therap's score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Briacell Therap	Neutral
Spruce Biosciences	Neutral

Briacell Therap has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.23, indicating that its stock price is 223% more volatile than the broader market.

Briacell Therap has higher earnings, but lower revenue than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Spruce Biosciences	$4.91M	24.81	-$38.97M	-$36.60	N/A

Spruce Biosciences has a consensus price target of $162.63, suggesting a potential upside of 267.14%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Spruce Biosciences beats Briacell Therap on 10 of the 14 factors compared between the two stocks.

How does Briacell Therap compare to Lixte Biotechnology?

Lixte Biotechnology (NASDAQ:LIXT) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 9.5% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 0.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lixte Biotechnology's return on equity of -134.91% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Briacell Therap	N/A	-153.53%	-129.26%

In the previous week, Lixte Biotechnology's average media sentiment score of 0.00 equaled Briacell Therap'saverage media sentiment score.

Company	Overall Sentiment
Lixte Biotechnology	Neutral
Briacell Therap	Neutral

Lixte Biotechnology has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

Summary

Lixte Biotechnology beats Briacell Therap on 6 of the 8 factors compared between the two stocks.

Get Briacell Therap News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCTX vs. The Competition

Export

Metric	Briacell Therap	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.97M	$3.54B	$6.81B	$12.94B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-0.42	7.33	279.92	25.45
Price / Sales	N/A	1,273.99	647.84	115.11
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	0.36	17.12	11.11	6.33
Net Income	-$26.31M	-$12.52M	$3.48B	$347.60M
7 Day Performance	-4.03%	1.99%	2.04%	2.78%
1 Month Performance	2.15%	-5.83%	-3.16%	-2.36%
1 Year Performance	-55.89%	50.13%	63.65%	20.74%

Briacell Therap Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCTX Briacell Therap	0.2759 of 5 stars	$3.31 -1.5%	N/A	-54.8%	$28.81M	N/A	N/A	8	Gap Up
NRXP NRx Pharmaceuticals	1.5733 of 5 stars	$3.36 -5.2%	$38.25 +1,039.7%	+25.1%	$121.59M	$1.23M	N/A	2
PEPG PepGen	3.0953 of 5 stars	$1.76 -4.1%	$11.50 +555.3%	+42.4%	$121.39M	N/A	N/A	30	Positive News Upcoming Earnings
ANIX Anixa Biosciences	4.5749 of 5 stars	$3.53 +0.3%	$8.50 +140.8%	+13.3%	$120.09M	$210K	N/A	5	News Coverage Positive News
SPRB Spruce Biosciences	2.4569 of 5 stars	$41.51 -0.2%	$162.63 +291.8%	N/A	$113.68M	$4.91M	N/A	20	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCTX) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Briacell Therap (BCTX) Competitors

BCTX vs. NRXP, PEPG, ANIX, SPRB, and LIXT

How does Briacell Therap compare to NRx Pharmaceuticals?

Summary

How does Briacell Therap compare to PepGen?

Summary

How does Briacell Therap compare to Anixa Biosciences?

Summary

How does Briacell Therap compare to Spruce Biosciences?

Summary

How does Briacell Therap compare to Lixte Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Briacell Therap (BCTX) Competitors

BCTX vs. NRXP, PEPG, ANIX, SPRB, and LIXT

How does Briacell Therap compare to NRx Pharmaceuticals?

Does the media favor NRXP or BCTX?

Is NRXP or BCTX more profitable?

Do analysts recommend NRXP or BCTX?

Do insiders & institutionals have more ownership in NRXP or BCTX?

Which has better valuation & earnings, NRXP or BCTX?

Which has more risk and volatility, NRXP or BCTX?

Summary

How does Briacell Therap compare to PepGen?

Which has more risk & volatility, PEPG or BCTX?

Do analysts recommend PEPG or BCTX?

Does the media prefer PEPG or BCTX?

Which has stronger earnings and valuation, PEPG or BCTX?

Do insiders and institutionals hold more shares of PEPG or BCTX?

Is PEPG or BCTX more profitable?

Summary

How does Briacell Therap compare to Anixa Biosciences?

Which has more volatility & risk, ANIX or BCTX?

Do insiders and institutionals hold more shares of ANIX or BCTX?

Which has higher valuation & earnings, ANIX or BCTX?

Is ANIX or BCTX more profitable?

Do analysts recommend ANIX or BCTX?

Does the media prefer ANIX or BCTX?

Summary

How does Briacell Therap compare to Spruce Biosciences?

Is BCTX or SPRB more profitable?

Do institutionals & insiders hold more shares of BCTX or SPRB?

Does the media favor BCTX or SPRB?

Which has more risk and volatility, BCTX or SPRB?

Which has higher earnings & valuation, BCTX or SPRB?

Do analysts recommend BCTX or SPRB?

Summary

How does Briacell Therap compare to Lixte Biotechnology?

Do insiders & institutionals hold more shares of LIXT or BCTX?

Do analysts recommend LIXT or BCTX?

Is LIXT or BCTX more profitable?

Does the media prefer LIXT or BCTX?

Which has more risk and volatility, LIXT or BCTX?

Which has stronger valuation and earnings, LIXT or BCTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools